RECOVERY Respiratory Support: Respiratory Strategies in patients with coronavirus COVID-19 – CPAP, high-flow nasal oxygen, and standard care

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered		
02/04/2020		[X] Protocol		
Registration date 06/04/2020	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited	Condition category	Individual participant data		
25/01/2022	Respiratory			

Plain English summary of protocol

Current plain English summary as of 04/05/2021:

Background and study aims:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged at the end of 2019 as a novel coronavirus. It has been declared as a global pandemic. Some people develop no symptoms, whilst others develop worsening breathing problems and may die. Throughout the world, a huge burden has been placed on intensive care units due to the number of people with worsening breathing problems that need to be placed on a ventilator (breathing machine). It is essential that we avoid ventilator use wherever possible to allow as many individuals as possible to benefit.

In this trial, we will test whether two treatments are better than standard treatment at preventing people from dying or needing to go on a ventilator.

Who can participate?

Adult hospital inpatients with suspected or proven COVID-19

What does the study involve?

Individuals that have or are believed to have COVID-19 that are requiring a certain amount of oxygen will be randomly allocated to receive one of three interventions. In the first group, participants will be placed on a tight-fitting mask (CPAP). In the second group, participants will receive oxygen blown quickly up their nose by a machine (HFNO). In the third arm, participants will receive standard treatment (a normal oxygen mask). Both CPAP and HFNO are already used routinely in the NHS for other conditions.

Where possible, we will seek informed consent from participants prior to trial enrolment. In some cases, the urgency of treatment may require that participants are enrolled and their

consent sought later. This is because some participants are likely to be confused and, due to COVID-19, visiting is restricted. In addition, for treatments to be effective, they will need to be started as quickly as possible to have the best possible outcomes.

We will record the need for people to be placed on a ventilator and death over a 30-day period. We will also see how long people spend on intensive care units and in hospital.

What are the possible benefits and risks of participating?

The planned interventions are already in routine use across NHS Hospitals. The interventions (HFNO and CPAP) may help to reduce the need for patients to go on a ventilator. However, they have some side-effects such as nausea, dryness to the mouth and nose, and pressure sores to the face.

Where is the study run from?
The trial is led by the University of Warwick Clinical Trials Unit

When is the study starting and how long is it expected to run for? From March 2020 to June 2021

Who is funding the study?
The National Institute for Health Research (UK)

Who is the main contact?

Unfortunately, this study is not recruiting public volunteers at this time. This is because the research isn't ready for volunteers yet or the researchers are directly identifying volunteers in certain areas or hospitals. Please do not contact the research team as they will not be able to respond. For more information about COVID-19 research, visit the Be Part of Research homepage.

Previous plain English summary:

Background and study aims:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged at the end of 2019 as a novel coronavirus. It has been declared as a global pandemic. Some people develop no symptoms, whilst others develop worsening breathing problems and may die. Throughout the world, a huge burden has been placed on intensive care units due to the number of people with worsening breathing problems that need to be placed on a ventilator (breathing machine). It is essential that we avoid ventilator use wherever possible to allow as many individuals as possible to benefit.

In this trial, we will test whether two treatments are better than standard treatment at preventing people from dying or needing to go on a ventilator.

Who can participate?

Adult patients with suspected or proven COVID-19 admitted to hospital

What does the study involve?

Individuals that have or are believed to have COVID-19 that are requiring a certain amount of oxygen will be randomly allocated to receive one of three interventions. In the first group, participants will be placed on a tight-fitting mask (CPAP). In the second group, participants will receive oxygen blown quickly up their nose by a machine (HFNO). In the third arm, participants will receive standard treatment (a normal oxygen mask). Both CPAP and HFNO are already used routinely in the NHS for other conditions.

Due to the urgency of treatment, we plan to enrol potential participants immediately and seek their consent later. This is because many participants are likely to be confused and due to COVID-19 visiting will be restricted. In addition, for the treatments to be effective, they will need to be started as quickly as possible to have the best outcomes.

We will record the need for people to be placed on a ventilator and death over a 30-day period. We will also see how long people spend on intensive care units and in hospital.

What are the possible benefits and risks of participating?

The planned interventions are already in routine use across NHS Hospitals. The interventions (HFNO and CPAP) may help to reduce the need for patients to go on a ventilator. However, they have some side-effects such as nausea, dryness to the mouth and nose, and pressure sores to the face.

Where is the study run from?
The trial is led by the University of Warwick Clinical Trials Unit

When is the study starting and how long is it expected to run for? From March 2020 to May 2021

Who is funding the study?
The National Institute for Health Research (UK)

Who is the main contact?

Unfortunately, this study is not recruiting public volunteers at this time. This is because the research isn't ready for volunteers yet or the researchers are directly identifying volunteers in certain areas or hospitals. Please do not contact the research team as they will not be able to respond. For more information about COVID-19 research, visit the Be Part of Research homepage.

Study website

https://warwick.ac.uk/fac/sci/med/research/ctu/trials/recovery-rs/

Contact information

Type(s)

Public

Contact name

Dr Keith Couper

ORCID ID

http://orcid.org/0000-0003-2123-2022

Contact details

Clinical Trials Unit Warwick Medical School University of Warwick Coventry United Kingdom CV4 7AL +442476151179 k.couper@warwick.ac.uk

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

282338

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

Sponsor: 26/19-20, IRAS 282338

Study information

Scientific Title

In adult patients with known or suspected COVID-19, does the use of Continuous Positive Airway Pressure (CPAP) or high-flow nasal oxygen (HFNO), compared with standard care reduce mortality or need for tracheal intubation?

Acronym

Recovery-RS

Study objectives

CPAP is superior to standard care in reducing mortality or need for tracheal intubation in COVID-19 patients

HFNO is superior to standard care in reducing mortality or need for tracheal intubation in COVID-19 patients

CPAP is superior to HFNO in reducing mortality or need for tracheal intubation in COVID-19 patients

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 03/04/2020, the London - Brighton & Sussex Research Ethics Committee (Health Research Authority, Ground Floor, Skipton House, 80 London Road, London SE1 6LH; +44 0207 104 8241; brightonandsussex.rec@hra.nhs.uk), ref: 20/HRA/1696

Study design

Adaptive (group-sequential), pragmatic, randomised controlled, open-label, multi-centre, effectiveness trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Respiratory failure in patients with known or suspected COVID-19 (SARS-CoV-2 infection)

Interventions

Patients will be randomised in a 1:1:1 ratio to:

Arm 1: Continuous positive airway pressure (CPAP), administered according to local protocol/guidelines. Administration will be left to clinical discretion.

Arm 2: High flow nasal oxygen (HFNO) will be administered according to local protocol /guidelines. Administration will be left to clinical discretion.

Arm 3: Standard care. Standard oxygen therapy according to local protocol/guidelines.

Intervention Type

Procedure/Surgery

Primary outcome measure

Composite outcome comprising tracheal intubation or mortality within 30 days. Mortality will be reported from hospital records up until discharge and tracked after discharge. Intubation will be obtained from hospital data.

Secondary outcome measures

Current secondary outcome measures as of 04/05/2021:

All outcome measures are assessed at up to 30-days or hospital discharge, whichever is later, and obtained from hospital records unless otherwise specified.

- 1. Intubation rate
- 2. Time to intubation
- 3. Time to death (mortality), obtained from hospital record or other source
- 4. Mortality in critical care (level 2/3)
- 5. Mortality during hospital stay
- 6. Mortality at 30 days, obtained from hospital record or other source
- 7. Length of stay in critical care (level 2/3)
- 8. Length of stay in hospital
- 9. Duration of invasive ventilation
- 10. Admission to ICU

Previous secondary outcome measures:

All outcome measures are assessed at up to 30-days or hospital discharge, whichever is later, and obtained from hospital records unless otherwise specified.

- 1. Intubation rate
- 2. Time to intubation
- 3. Time to death (mortality), obtained from hospital record or other source
- 4. Mortality in critical care (level 2/3)
- 5. Mortality during hospital stay
- 6. Mortality at 30 days, obtained from hospital record or other source
- 7. Length of stay in critical care (level 2/3)
- 8. Length of stay in hospital

Overall study start date

30/03/2020

Completion date

02/06/2021

Eligibility

Key inclusion criteria

Current participant inclusion criteria as of 04/05/2021:

- 1. Adults ≥18 years
- 2. Hospital inpatient with suspected or proven COVID-19
- 3. FiO2 ≥0.4 and SpO2 ≤94%
- 4. Plan for escalation to intubation if needed

Previous participant inclusion criteria:

- 1. Adults ≥ 18 years
- 2. Admitted to hospital with suspected or proven COVID-19
- 3. On 40% oxygen (or greater) with SpO2 <94%
- 4. Plan for escalation to intubation if needed

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

4002

Key exclusion criteria

Current participant exclusion criteria as of 04/05/2021:

- 1. Planned intubation and mechanical ventilation imminent within 1 hour
- 2. Known or clinically apparent pregnancy
- 3. Any absolute contraindication to CPAP or HFNO

- 4. Decision not to intubate due to ceiling of treatment or withdrawal of treatment anticipated
- 5. Equipment for both CPAP and HFNO not available

Previous participant exclusion criteria:

- 1. Planned intubation and mechanical ventilation imminent within 1 hour
- 2. Known or clinically apparent pregnancy
- 3. Any absolute contraindication to CPAP or HFNO
- 4. Decision not to intubate due to ceiling of treatment or withdrawal of care anticipated
- 5. Equipment for both CPAP and HFNO not available

Date of first enrolment

06/04/2020

Date of final enrolment

03/05/2021

Locations

Countries of recruitment

England

Northern Ireland

Scotland

United Kingdom

Wales

Study participating centre Warwick Clinical Trials Unit

Warwick Medical School University of Warwick Coventry United Kingdom CV4 7AL

Study participating centre Aintree Hospital

Lower Lane Liverpool United Kingdom L9 7AL

Altnagelvin Hospital

Glenshane Road Londonderry United Kingdom BT47 6SB

Study participating centre Barnet Hospital

Wellhouse Lane Barnet United Kingdom EN5 3DJ

Study participating centre Bedford Hospital

Kempston Road Bedford United Kingdom MK42 9DJ

Study participating centre Belfast City Hospital

51 Lisburn Road Belfast United Kingdom BT9 7AB

Study participating centre Castle Hill Hospital

Castle Road Cottingham United Kingdom HU16 5JQ

Study participating centre Charing Cross Hospital (Lead Centre)

Fulham Palace Road London United Kingdom W6 8RF

Study participating centre Colchester General Hospital

Turner Road Colchester United Kingdom CO4 5JL

Study participating centre Conquest Hospital, Hastings

The Ridge St. Leonards-On-Sea United Kingdom TN37 7RD

Study participating centre Croydon University Hospital

London Road Croydon United Kingdom CR7 7YE

Study participating centre Derriford Hospital

Derriford Road Crownhill Plymouth United Kingdom PL6 8DH

Study participating centre Diana, Princess Of Wales Hospital

Scartho Road Grimsby United Kingdom DN33 2BA

Study participating centre Eastbourne District General

Kings Drive

Eastbourne United Kingdom BN21 2UD

Study participating centre Fairfield General Hospital

Rochdale Old Road Bury United Kingdom BL9 7TD

Study participating centre Freeman Hospital

Freeman Road High Heaton Newcastle Upon Tyne United Kingdom NE7 7DN

Study participating centre Glenfield Hospital

Groby Road Leicester United Kingdom LE3 9QP

Study participating centre Good Hope Hospital

Rectory Road Sutton Coldfield United Kingdom B75 7RR

Study participating centre Harefield Hospital

Hill End Road Harefield United Kingdom UB9 6JH

Study participating centre Heartlands Hospital

Bordesley Green East Birmingham United Kingdom B9 5SS

Study participating centre Hull Royal Infirmary

Anlaby Road Hull United Kingdom HU3 2JZ

Study participating centre Inverclyde Royal Hospital

Larkfield Road Greenock United Kingdom PA16 0XN

Study participating centre Ipswich Hospital

Heath Road Ipswich United Kingdom IP4 5PD

Study participating centre James Paget University Hospital

Lowestoft Road Gorleston Great Yarmouth United Kingdom NR31 6LA

Study participating centre Jersey General Hospital

The Parade Jersey United Kingdom JE1 3UH

Study participating centre Kent & Canterbury

Ethelbert Road Canterbury United Kingdom CT1 3NG

Study participating centre King's College (Denmark Hill)

Denmark Hill London United Kingdom SE5 9RS

Study participating centre Leighton Hospital

Leighton Crewe United Kingdom CW1 4QJ

Study participating centre

Lister HospitalCoreys Mill Lane
Stevenage
United Kingdom

SG1 4AB

Study participating centre Macclesfield District General Hospital

Victoria Road Macclesfield United Kingdom SK10 3BL

Study participating centre

Manor Hospital

Moat Road Walsall United Kingdom WS2 9PS

Study participating centre Medway Maritime Hospital

Windmill Road Gillingham United Kingdom ME7 5NY

Study participating centre Musgrove Park Hospital

Musgrove Park Taunton United Kingdom TA1 5DA

Study participating centre New Cross Hospital

Wolverhampton Road Heath Town Wolverhampton United Kingdom WV10 0QP

Study participating centre
Norfolk And Norwich University Hospital

Colney Lane Colney Norwich United Kingdom NR4 7UY

Study participating centre North Manchester

Delaunays Road

Manchester United Kingdom M8 5RB

Study participating centre Nottingham City Hospital

Hucknall Road Nottingham United Kingdom NG5 1PB

Study participating centre Princess Of Wales Hospital (Wales)

Coity Road Bridgend United Kingdom CF31 1RQ

Study participating centre Princess Royal Hospital, Telford

Apley Castle
Grainger Drive
Telford
United Kingdom
TF1 6TF

Study participating centre Princess Royal University Hospital

Farnborough Common Orpington United Kingdom BR6 8ND

Study participating centre Queen Alexandra Hospital

Southwick Hill Road Cosham Portsmouth United Kingdom PO6 3LY

Study participating centre Queen Elizabeth Hospital – Gateshead

Sheriff Hill Gateshead United Kingdom NE9 6SX

Study participating centre Queen Elizabeth Hospital (Birmingham)

Queen Elizabeth Medical Centre Edgbaston Birmingham United Kingdom B15 2TH

Study participating centre Queen Elizabeth University Hospital, Glasgow

1345 Govan Road Glasgow United Kingdom G51 4TF

Study participating centre Queens Medical Centre

Nottingham University Hospital Derby Road Nottingham United Kingdom NG7 2UH

Study participating centre Raigmore Hospital

Old Perth Rd Inverness United Kingdom IV2 3UJ

Study participating centre

Royal Alexandra Hospital, Paisley

Corsebar Road Paisley United Kingdom PA2 9PN

Study participating centre Royal Brompton

Sydney Street London United Kingdom SW3 6NP

Study participating centre Royal Gwent Hospital

Cardiff Road Newport Gwent United Kingdom NP20 2UB

Study participating centre Royal Liverpool University Hospital

Prescot Street Liverpool United Kingdom L7 8XP

Study participating centre Royal Marsden (London)

Fulham Road London United Kingdom SW3 6JJ

Study participating centre Royal Marsden (Surrey)

Downs Road Sutton United Kingdom SM2 5PT

Study participating centre **Royal Oldham Hospital**

Rochdale Road Oldham **United Kingdom** OL1 2JH

Study participating centre Russell's Hall

Pensnett Road Dudley United Kingdom DY1 2HQ

Study participating centre Salford Royal Hospital

Stott Lane Salford United Kingdom M6 8HD

Study participating centre Scunthorpe General Hospital

Cliff Gardens Scunthorpe United Kingdom **DN15 7BH**

Study participating centre South Tyneside District Hospital

Harton Ln South Shields United Kingdom NE34 0PL

Study participating centre Southmead Hospital

Southmead Road

Westbury-On-Trym Bristol United Kingdom BS10 5NB

Study participating centre St George's Hospital

Blackshaw Road London United Kingdom SW17 0QT

Study participating centre St Mary's Hospital

Praed Street London United Kingdom W2 1NY

Study participating centre St Thomas' Hospital

Westminster Bridge Road London United Kingdom SE1 7EH

Study participating centre Stepping Hill Hospital

Poplar Grove Stockport United Kingdom SK2 7JE

Study participating centre Sunderland Royal Hospital

Kayll Road Sunderland United Kingdom SR4 7TP

Study participating centre The Christie NHS Foundation Trust

550 Wilmslow Road Withington Manchester United Kingdom M20 4BX

Study participating centre The Grange University Hospital

Caerleon Road Cwmbran United Kingdom NP44 8YN

Study participating centre The Royal Victoria Infirmary

Queen Victoria Road Newcastle Upon Tyne United Kingdom NE1 4LP

Study participating centre Torbay Hospital

Newton Road Torquay United Kingdom TQ2 7AA

Study participating centre University Hospital Southampton

Tremona Road Southampton United Kingdom SO16 6YD

Study participating centre Victoria Hospital Hayfield Road

Kirkcaldy

United Kingdom KY2 5AH

Study participating centre Warwick Hospital

Lakin Road Warwick United Kingdom CV34 5BW

Study participating centre Watford General Hospital

Vicarage Road Watford United Kingdom WD18 0HB

Study participating centre West Suffolk Hospital

Hardwick Lane Bury St. Edmunds United Kingdom IP33 2QZ

Study participating centre William Harvey Hospital, Ashford

Kennington Road Willesborough Ashford United Kingdom TN24 0LZ

Study participating centre Wishaw General Hospital

50 Netherton Street Wishaw United Kingdom ML2 0DP

Study participating centre Wrexham Maelor Hospital

Croesnewydd Road Wrexham Technology Park Wrexham United Kingdom LL13 7TD

Study participating centre Wythenshawe Hospital

Southmoor Road Wythenshawe Manchester United Kingdom M23 9LT

Sponsor information

Organisation

University of Warwick

Sponsor details

Gibbet Hill Road
Coventry
Coventry
England
United Kingdom
CV4 7AL
+44 247 652 2746
wmssponsorship@warwick.ac.uk

Sponsor type

University/education

Website

http://www2.warwick.ac.uk/

ROR

https://ror.org/01a77tt86

Funder(s)

Funder type

Funder Name

National Institute for Health Research

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Trial results will be published as soon as data are analysed. Dissemination will include development of lay summaries and publication in a peer-reviewed journal.

Intention to publish date

03/10/2021

Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	protocol	29/07/2020	03/08/2020	Yes	No
Preprint results		04/08/2021	31/08/2021	No	No
Results article		24/01/2022	25/01/2022	Yes	No
HRA research summary			28/06/2023	No	No